鯽魚複方製劑改善代謝症候群之研究

代謝症候群(metabolism syndrome)是一種包含肥胖、血壓偏高、血糖偏高以及血脂異常等多項危險因子綜合表現的臨床徵候。鯽魚複方製劑(Carassius auratus complex formula，CACF)是以鯽魚與山藥、枸杞、熟地黃等中藥熬製而成的傳統中藥配方，應用於治療糖尿病。本研究擬證明CACF是否具有改善代謝症候群之能力，先以及高脂飲食(high fat diet，HFD)合併streptozotocin (STZ)誘發代謝症候群之動物模式，在給予CACF後發現，其可降低血脂、降血糖、提升血清胰島素、降低胰島素阻抗；並發現CACF可抑制由HFD合併STZ所誘導血清中發炎因子TNF-α、IL-6及脂激素leptin/adiponectin之分泌量。另測量肝臟抗氧化相關指標(TBARS、GSH、GPx)，並以H&E染色觀察肝臟和腎臟當中異常組織型態變化發現，CACF對於各組織脂質過氧化表現、肝臟脂肪堆積及蛋白尿現象也都有減緩之趨勢。接著利用氧化壓力H2O2引發大鼠胰島β細胞(RIN-m5F)凋亡之細胞模式再給予CACF後觀察發現，CACF可經由增加p-Bad與減少Bax及Bid來保護H2O2刺激RIN-m5F細胞凋亡(apoptosis)的產生。由以上實驗結果顯示，CACF具有保護胰島β細胞走向細胞凋亡作用、以及降血脂、抗氧化和抗發炎之活性，並能抑制代謝症侯群之表癥。

關鍵字

代謝症候群；鯽魚複方製劑；胰島素阻抗；降血脂；抗氧化；抗發炎；胰島

並列摘要

Metabolic syndrome is characterized by obesity, hypertension, hyperglycemia and dyslipidemia as well as a cluster of risk factors. Carassius auratus complex formula (CACF), including Carassius auratus, Rhizoma dioscoreae, Lycium chinense, and Rehmannia glutinosa Libosch, is a combination prescription of traditional Chinese medicine, which has been used to treat diabetes in ancient China. In vivo study, the BALB/c mice were fed with high fat diet (HFD) combined streptozotocin (STZ) supplemented with CACF to observe the effect on metabolic syndrome. In the animal model, CACF could decrease serum levels blood sugar, insulin and cytokines (TNF-α, IL-6 and leptin/adiponectin) resurved insulin resistance. Feeding CACF to mice reduced TBARS, and increased liver levels of GSH and GPx, and antioxidant enzyme. CACF could decrease lipid peroxidation in the liver and kidney, lipid accumulation in the liver and content of urine protein. In vitro study, CACF decreased apoptosis via up-regulation of p-Bad and down-regulations of phosphor-p53 and Bid on RIN-m5F cells. These results suggest that inhibit apoptosis in β cell, and decreased hyperlipid, hyperglycemia and inflammation.

並列關鍵字

metabolic syndrome ； Carassius auratus complex formula ； insulin resistance ； apoptosis ； hyperlipidemia ； hyperglycemia ； inflammation.

參考文獻

[71] 行政院衛生署，健康食品安全性評估方法。2010

[1] Isomaa B., Almgren P., Tuomi T., Forsen B., Lathi K., Nissen M., Taskinen M. R., Groop L.:Cardiovascular morbidity and mortality associated with the metabolic syndrome.Diabetes care. 2001,24:683-689.

[3] Reaven G. M.,Role of insulin resistance in human disease.Diabetes. 1988,37:595-1607

[4] Malmberg K., Yusuf S., Gerstein H. C., Brown J.,Zhao F.,Hunt D., Piegas L., Calvin J., Keltai M., Budaj A.:Impact of diabetes on long-term prognosis in patients with undstble angina and non-q-wave myocardial infarction: Results of the oasis(organization to assess strategies for ischemic syndrome)registry. Circulation. 2000,102:1014-1019.

[5] Alberti K. G.,Zimmet P. Z.:Definition,diagnosis and classification of diabetes mellitus and its complications. Part1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consulation.Diabe med. 1998, 15:539-553.

國際替代計量

鯽魚複方製劑改善代謝症候群之研究

未授權

主題瀏覽